Paraneoplastic giant cell arteritis and prostate cancer: A case report of a not common association

Figueiredo, C.C.R.; Amaral, Marta; Rodrigues, Élio; Silva, Rui; Vilão, Óscar

doi:10.1002/ccr3.3785

Cited by 6 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various paraneoplastic syndromes that have been reported to be associated with prostate cancer are SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome [ 4 ], hyperfibrinolysis [ 5 ], giant cell arteritis [ 6 ], Cushing syndrome [ 7 ], Stauffer syndrome [ 8 ], anti-Hu mediated intestinal pseudo-obstruction [ 9 ], and SIADH (syndrome of inappropriate antidiuretic hormone secretion) [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation

Sidda¹,

Manu²,

Abdallah³

et al. 2022

Cureus

View full text Add to dashboard Cite

Paraneoplastic syndromes are defined as tumor‐associated indirect systemic effects. Prostate cancer-associated paraneoplastic syndromes typically have endocrine, neurologic, and dermatologic manifestations. Reports have suggested up to 70% of metastatic prostate cancers manifest as paraneoplastic entities. Although common in hematological malignancies, it is rare for prostate cancer and other solid tumors to be associated with immune-mediated cytopenias such as Evans syndrome. Based on our PubMed search for the keywords Evans syndrome and prostate cancer, only one other case has been reported in the literature with this association. We report the second such case in a 63-year-old male who initially presented with hemolytic anemia and thrombocytopenia. He was diagnosed with Evans syndrome with initial responses to both steroids and intravenous immunoglobulin. Extensive workup, including an eventual bone marrow biopsy, revealed metastatic prostate cancer with transformation to small cell neuroendocrine carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation

Sidda¹,

Manu²,

Abdallah³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The patient underwent radical orchidectomy, and GCA was confirmed in histopathological assessment [11]. In the existing literature, the association between GCA as a paraneoplastic condition and the development of prostate cancer (PCa) was also hypothesized [12].…”

Section: Giant Cell Arteritis (Gca)mentioning

confidence: 99%

Urological Manifestations of the Systemic Vasculitides—A Scoping Review

Nowak

Krajewski

Krajewska

et al. 2021

Uro

View full text Add to dashboard Cite

Background: Vasculitides are specific inflammations of the blood vessel wall that can take place in any organ system of the human body. They may occur as a primary process (primary systemic vasculitides, PSV) or may be secondary to another underlying disease. In general, in association with the specific type of vasculitis, affected vessels vary in size, type, and location. In the following scoping review, we present clinical characteristics and manifestations of PSV with reference to the genitourinary system. Materials and methods: A non-systematic search of the relevant literature was conducted using three electronic databases (PubMed, Embase, and Web of Science) up to 29 October 2021. Results: Urogenital manifestations of PSV are infrequent, with the most commonly reported findings as prostatic or testicular involvements. However, almost all other organs of the genitourinary system can be affected. Conclusions: Because of the clinical heterogeneity and non-specific symptoms, the proper diagnosis of PSV is often delayed and constricted. Fast identification of urological manifestations of vasculitides is essential in implementing appropriate therapy and avoiding unnecessary, harmful, and invasive surgery.

show abstract

“…The following are available online at : Supplementary Material S1: PRISMA 2020 Checklist [ 54 ]; Supplementary Material S2: List of Excluded Studies [ 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ].…”

mentioning

confidence: 99%

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review

Abufaraj,

Ramadan,

Alkhatib

2024

Current Oncology

View full text Add to dashboard Cite

Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language articles from January 2017 to September 2023, identifying 17 studies meeting PRISMA guidelines for NEPC and associated PNS. A total of 17 articles were included in the review. Among these, Cushing’s Syndrome (CS) due to ectopic Adrenocorticotropic hormone (ACTH) secretion was the most commonly reported PNS. Other PNS included syndrome of inappropriate Anti-Diuretic Hormone secretion (SIADH), Anti-Hu-mediated chronic intestinal pseudo-obstruction (CIPO), limbic encephalitis, Evans Syndrome, hypercalcemia, dermatomyositis, and polycythemia. Many patients had a history of prostate adenocarcinoma treated with androgen deprivation therapy (ADT) before neuroendocrine features developed. The mean age was 65.5 years, with a maximum survival of 9 months post-diagnosis. NEPC is becoming an increasingly more common subtype of PCa that can result in various PNS. This makes the diagnosis and treatment of NEPC challenging. Further research is crucial to understanding these syndromes and developing standardized, targeted treatments to improve patient survival.

show abstract

Paraneoplastic giant cell arteritis and prostate cancer: A case report of a not common association

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 6 publications

References 4 publications

Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation

Paraneoplastic Evans Syndrome in a Patient With Prostate Cancer With Small Cell Transformation

Urological Manifestations of the Systemic Vasculitides—A Scoping Review

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review

Contact Info

Product

Resources

About